NRI

Concord Biotech Ltd

Sector Pharmaceuticals
BSE 543960
NSE CONCORDBIO
1,682.40
-9.90 (-0.59 %)
Buy
B
Sell
S
NSE BSE

Overview

Day Low

1,482.60

Day High

1,728.95

52 Week Low

1,327.05

52 Week High

2,664.00

All Time Low

900.05

All Time High

2,664.00

Open

1,668.40

Close

1,692.30

Volume

1,130,976

Mkt cap (Cr)

17,600.60

P/E ratio

53.99

P/B ratio

0.09%

Div yield

0.52%

6M return

7.02%

1Y return

20.16%

1D 1W 1M 3M 6M 1Yr 3Yr 5Yr 10Yr Max
Price PE Ratio
 

We appreciate your patience. Your content is on the way.

SWOT Analysis

  • S
  • W
  • O
  • T

Technical Analysis

Moving Averages

EMA SMA
 

We appreciate your patience. Your content is on the way.

1,682.40 -0.59%

Current Price

  • Bullish Moving Averages
  • Bearish Moving Averages

Resistance and support

 

We appreciate your patience. Your content is on the way.

Company Financials

  • Profit and loss statement
  • Balance sheet
  • Quarterly Result
  • Ratio
 

We appreciate your patience. Your content is on the way.

Quick Results Snapshot

 

We appreciate your patience. Your content is on the way.

Shareholding Pattern

Summary

 

We appreciate your patience. Your content is on the way.

 

We appreciate your patience. Your content is on the way.

Historical Promoter Summary

 

We appreciate your patience. Your content is on the way.

Promoter Holding(%)

Historical FII Holdings

 

We appreciate your patience. Your content is on the way.

FII Holding(%)

Historical MF Holdings

 

We appreciate your patience. Your content is on the way.

MF Holding(%)

Stocks Comparison
Table Chart

 

We appreciate your patience. Your content is on the way.

Corporate Action

  • Announcement
  • Board Meeting
  • Dividend
  • Split
  • Rights
  • Events

Insider & Institutional Activity

  • Bulk Block Deals
  • Insider Trading & SAST
 

We appreciate your patience. Your content is on the way.

About Concord Biotech Ltd

Stock PE (TTM)

53.99

Promoter Holding

44.08%

Book Value

152.0204

ROCE

29.05%

ROE

21.88%

Concord Biotech Limited was originally incorporated as `Servomed Pharmaceuticals Private Limited` at Ahmedabad, Gujarat as a Private Limited Company dated November 23, 1984, issued by the Registrar of Companies. Thereafter, name of the Company was changed to `Concord Biotech Limited` dated February 16, 2001, which became a Public Company and a fresh Certificate of Incorporation dated November 7, 2001 was issued by the RoC. The Company is an India-based bio pharma and one of the leading global developers and manufacturers of select fermentation-based APIs across immunosuppressants and oncology in terms of market share, based on volume in supplying to over 70 countries including regulated markets, such as the United States, Europe and Japan, and India. Presently, it is engaged in research and development, manufacturing, marketing and selling of pharmaceutical products. Its API manufacturing facilities are located at Dholka and Limbasi, and formulations facility at Valthera in Gujarat. In 2000, the Company was acquired by the Promoter, Mr. Sudhir Vaid. In 2016, the Company launched formulation business in India as well as emerging markets, including Nepal, Mexico, Indonesia, Thailand, Ecuador, Kenya, Singapore and Paraguay, and have further expanded to the United States. It established a facility at Valthera, Gujarat. It set up a joint venture in Japan to grow business in 2018. In 2019, the Company received two ANDA approvals. It expanded their business into critical care segment in India. It commenced marketing of Mycophenolate Mofetil Capsules USP 250 mg. In 2020, Mycophenolate Sodium Tablets got launched in the US market. The Company added a new manufacturing unit at Limbasi, which commenced operations in July, 2021. As of March 31, 2022, the Company had 6 fermentation-based immunosuppressant APIs, including tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus and pimecrolimus. It had 3 manufacturing facilities in the state of Gujarat, India, comprising API manufacturing facilities in Dholka and Limbasi and a formulation manufacturing facility in Valthera, which were commercialized in 2000, 2021 and 2016, respectively. Their total annual installed fermentation capacity for APIs was 1,250 m3, as of March 31, 2022. It had a total of 41 manufacturing blocks and 387 reactors in the Dholka and Limbasi facilities. In August 2023, Company made an Initial Public Offer by issuing 20,925,652 Equity Shares aggregating to Rs 1551 Crores through Offer for Sale. The Company has launched 21 new formulations products in 2024.

Concord Biotech share price as on 18 Feb 2025 is Rs. 1682.4. Over the past 6 months, the Concord Biotech share price has increased by 7.02% and in the last one year, it has increased by 20.16%. The 52-week low for Concord Biotech share price was Rs. 1327.05 and 52-week high was Rs. 2664.

Read More
Registered Office  
Registrars  
Management  
Listing Info  

543960

CONCORDBIO

INE338H01029

Jul

Concord Biotech Ltd FAQs

You can buy Concord Biotech Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Concord Biotech Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Feb 17, 2025 03:57 PM the closing price of Concord Biotech Ltd was Rs.1,682.40.

The latest PE ratio of Concord Biotech Ltd as of Feb 17, 2025 03:57 PM is 53.99

The latest PB ratio of Concord Biotech Ltd as of Feb 17, 2025 03:57 PM is 0.09

The 52-week high of Concord Biotech Ltd share price is Rs. 2,664.00 while the 52-week low is Rs. 1,327.05

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of Feb 17, 2025 03:57 PM, the market cap of Concord Biotech Ltd stood at Rs. 17,600.60 Cr.

Market Outlook

View all
 

We appreciate your patience. Your content is on the way.